Franklin Street Advisors Inc. NC increased its holdings in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) by 236.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 54,060 shares of the biopharmaceutical company’s stock after buying an additional 38,000 shares during the quarter. Franklin Street Advisors Inc. NC owned 0.10% of Intra-Cellular Therapies worth $783,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in ITCI. Perceptive Advisors LLC bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth $14,667,000. Wasatch Advisors Inc. lifted its position in shares of Intra-Cellular Therapies by 65.1% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock worth $20,611,000 after buying an additional 654,400 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth $8,663,000. Dimensional Fund Advisors LP lifted its position in shares of Intra-Cellular Therapies by 419.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 647,187 shares of the biopharmaceutical company’s stock worth $8,038,000 after buying an additional 522,565 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Intra-Cellular Therapies by 336.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock worth $7,213,000 after buying an additional 447,586 shares during the last quarter. Institutional investors and hedge funds own 74.47% of the company’s stock.
A number of equities analysts have issued reports on ITCI shares. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a report on Wednesday, November 8th. ValuEngine cut Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 5th. SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Wednesday, November 8th. Canaccord Genuity started coverage on Intra-Cellular Therapies in a report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price for the company. Finally, BidaskClub cut Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. Intra-Cellular Therapies has an average rating of “Buy” and an average price target of $26.11.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). Intra-Cellular Therapies had a negative return on equity of 27.40% and a negative net margin of 28,038.35%. The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.06 million. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. The business’s quarterly revenue was up 675.0% on a year-over-year basis. equities analysts expect that Intra-Cellular Therapies Inc. will post -2.13 earnings per share for the current year.
In other news, Director Christopher D. Alafi purchased 10,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were acquired at an average price of $15.55 per share, for a total transaction of $155,500.00. Following the completion of the acquisition, the director now owns 744,466 shares in the company, valued at $11,576,446.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Sharon Mates sold 18,750 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $15.75, for a total value of $295,312.50. Following the completion of the transaction, the chief executive officer now owns 1,107,457 shares in the company, valued at approximately $17,442,447.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 49,410 shares of company stock worth $802,481. 21.00% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Franklin Street Advisors Inc. NC Buys 38,000 Shares of Intra-Cellular Therapies Inc. (ITCI)” was posted by BBNS and is owned by of BBNS. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://baseballnewssource.com/markets/franklin-street-advisors-inc-nc-has-783000-position-in-intra-cellular-therapies-inc-itci/1823341.html.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.